Oberland Capital

Zealand Pharma A/S is a biotechnology company based in Copenhagen, Denmark, specializing in the discovery and development of peptide-based medicines. The company has a robust proprietary pipeline that includes several clinical candidates such as glepaglutide for short bowel syndrome and dasiglucagon for diabetes management and congenital hyperinsulinism. Zealand's first marketed product, lixisenatide, is a once-daily prandial GLP-1 analogue for Type 2 diabetes, available globally outside the U.S. through a collaboration with Sanofi. Additionally, Zealand has engaged in licensing collaborations with prominent pharmaceutical companies, including Sanofi, Helsinn Healthcare, and Boehringer Ingelheim, to advance its clinical programs and expand its portfolio. The company is committed to developing innovative therapies aimed at addressing unmet medical needs in various therapeutic areas.

Centessa Pharmaceuticals is a next-generation biopharmaceutical company that aims to reshape the traditional drug development process. The company applies an asset-centric R&D model at scale to advance a portfolio of highly validated programs led by industry-leading teams. Each program is developed by a Centessa Subsidiary and supported by a centralized infrastructure and the Centessa management team.

Esperion discovers and develops pharmaceutical products for the treatment of cardiovascular and metabolic diseases. Esperion intends to commercialize a novel class of drugs that focuses on a new treatment approach called "HDL Therapy," which is based on the Company's understanding of high-density lipoprotein, or HDL, function.

Mirum Pharmaceuticals is a biopharmaceutical company dedicated to developing and commercializing therapies for serious liver diseases. Founded in 2018 and based in Foster City, California, the company focuses on addressing rare and orphan diseases. Its lead product candidate, maralixibat, is an investigational oral drug currently in Phase 3 clinical trials for treating progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome (ALGS), and biliary atresia. Additionally, Mirum is developing volixibat, aimed at treating intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. The company’s commitment to innovative therapies positions it as a key player in the biopharmaceutical landscape dedicated to improving the lives of patients with debilitating liver conditions.

Primmune Therapeutics, Inc. is a biotechnology company based in San Diego, California, focused on developing small molecule, orally administered toll-like receptor 7 (TLR7) agonists for cancer immunotherapy. Founded in 2017, the company aims to stimulate innate immunity to enhance the effectiveness of adaptive cancer treatments, such as checkpoint inhibitors. Its TLR7 agonist is designed to activate the immune system by producing cytokines and chemokines that boost cellular responses and facilitate the activation of natural killer cells. This approach enables healthcare providers to target metastatic diseases more effectively and promotes B-cell proliferation and activation, ultimately improving overall response rates and treatment durability for patients.

NorthStar Medical Radioisotopes, LLC, founded in 2006 and based in Madison, Wisconsin, develops technologies and raw materials for the nuclear medicine market in the United States. The company specializes in diagnostic and therapeutic radioisotopes, offering products such as Molybdenum-99 and Technetium-99m, which are essential for imaging in various medical fields including neurology, oncology, and cardiology. Additionally, NorthStar provides therapeutic isotopes like Actinium-225 and Bismuth-213 for treating incurable diseases such as cancers and HIV. The company has also created the RadioGenix System, an advanced radioisotope separation platform that produces Technetium-99m from non-uranium based Molybdenum-99. By addressing supply challenges in the medical isotope market, NorthStar aims to enhance patient care and support clinical research initiatives.

Impact Biomedicines, Inc. is a biotechnology company focused on the research, development, and commercialization of innovative treatments for patients with myeloproliferative neoplasms and various cancers. Founded in 2016 and based in San Diego, California, the company is primarily developing fedratinib, a potent and highly selective oral small molecule JAK2 kinase inhibitor. This drug is aimed at treating myelofibrosis and polycythemia vera, with potential applications for acute myeloid leukemia and colorectal cancer. Impact Biomedicines operates as a subsidiary of Bristol-Myers Squibb Company.

Melinta Therapeutics, Inc. is a commercial-stage pharmaceutical company based in Morristown, New Jersey, specializing in the discovery, development, and commercialization of antibiotics aimed at treating bacterial infections. The company offers several products, including Baxdela, Vabomere, Orbactiv, and Minocin, which target acute bacterial skin infections and gram-negative pathogens. Melinta's mission is to address the urgent need for effective antibiotics to combat drug-resistant infections, a significant public health challenge. The company is actively advancing its late-stage investigational antibiotic, delafloxacin, currently in Phase 3 development for acute bacterial skin and skin structure infections. Additionally, Melinta is engaged in research aimed at developing new antibiotics to tackle resistant pathogens associated with serious hospital-acquired infections. Melinta Therapeutics maintains license agreements with several institutions, including Yale University and Wakunaga Pharmaceutical Co., Ltd., and is supported by investors such as Vatera Healthcare Partners and Warburg Pincus.